Arbutus Biopharma Corporation
Financials
Valuation Metrics
Arbutus Biopharma Corporation's Market Cap is $1.00B. At end of 2025 it was $922M. Ranked #2471 of 3,121 in US market (top 79%), #1016 of 1,463 on NASDAQ (top 69%), #189 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 71%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.00B | US#2,471/3,121 Sec#189/266 |
| Revenue | $182M | US#2,596/3,121 Sec#112/266 |
| Net Income | $153M | US#1,427/3,121 Sec#47/266 |
| Total Assets | $274M | US#2,936/3,121 Sec#220/266 |
| Net Assets | $259M | US#2,585/3,121 Sec#167/266 |
| Employees | 19 | US#2,773/3,121 Sec#222/266 |
| Value | ||
| P/E | 6.54x | US#113/3,121 Sec#5/266 |
| P/B | 3.87x | US#1,990/3,121 Sec#112/266 |
| P/S | 5.51x | US#2,367/3,121 Sec#80/266 |
| EV/EBITDA | 6.44x | US#308/3,121 Sec#8/266 |
| FCF Yield | -2.46% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | 59.16% | US#87/3,121 Sec#7/266 |
| ROA | 55.85% | US#6/3,121 Sec#2/266 |
| Op. Margin | 81.01% | US#20/3,121 Sec#1/266 |
| Revenue Growth | 1078.78% | US#19/3,121 Sec#11/266 |
| Financial Health | ||
| Debt Ratio | 5.91% | US#51/3,121 Sec#22/266 |
| Total Debt | $4M | US#2,935/3,121 Sec#225/266 |
| FCF | $-25M | US#2,448/3,121 Sec#99/266 |
| Cash | $19M | US#2,880/3,121 Sec#259/266 |
| Current Ratio | 81.42x | US#40/3,121 Sec#2/266 |
| Net Debt/EBITDA | -0.10x | US#531/3,121 Sec#31/266 |
| Performance | ||
| 1Y Return | 14.45% | US#1,332/3,121 Sec#164/266 |
| 1M Return | 4.75% | US#506/3,121 Sec#58/266 |
| From 52W High | -6.97% | US#476/3,121 Sec#33/266 |
| 1Y MDD | -25.86% | US#1,109/3,121 Sec#58/266 |
| Trading | ||
| Volume | 2,641,083 shares | US#663/3,121 Sec#64/266 |
| Trading Value | $13M | US#2,160/3,121 Sec#174/266 |
| Per Share | ||
| EPS | $0.77 | US#1,763/3,121 Sec#52/266 |
| BPS | $1.31 | US#2,655/3,121 Sec#192/266 |
Company Info
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.